No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Cuts Target Price to $20
Kyverna Therapeutics Is Maintained at Overweight by Morgan Stanley
Kyverna Therapeutics Analyst Ratings
Express News | Kyverna Therapeutics Inc : Morgan Stanley Cuts Target Price to $20 From $40
Kyverna Therapeutics Advances CAR T-Cell Therapy Trials
Express News | Kyverna Therapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing